APHINITY trial
E261835
The APHINITY trial is a large phase III clinical study that evaluated the addition of pertuzumab (Perjeta) to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
All labels observed (2)
| Label | Occurrences |
|---|---|
| APHINITY trial canonical | 1 |
| Adjuvant Pertuzumab and Herceptin IN Initial TherapY trial | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2371141 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: APHINITY trial Context triple: [Perjeta, clinicalTrial, APHINITY trial]
-
A.
EMERGE (Study 302)
EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
-
B.
ENGAGE (Study 301)
ENGAGE (Study 301) is a large Phase 3 clinical trial designed to evaluate the efficacy and safety of the anti-amyloid monoclonal antibody aducanumab (Aduhelm) in patients with early Alzheimer’s disease.
-
C.
ENSEMBLE trial
The ENSEMBLE trial was a large, global Phase 3 clinical study designed to evaluate the safety and efficacy of Janssen’s single-dose COVID-19 vaccine in preventing SARS-CoV-2 infection and severe disease.
-
D.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: APHINITY trial Target entity description: The APHINITY trial is a large phase III clinical study that evaluated the addition of pertuzumab (Perjeta) to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
-
A.
EMERGE (Study 302)
EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
-
B.
ENGAGE (Study 301)
ENGAGE (Study 301) is a large Phase 3 clinical trial designed to evaluate the efficacy and safety of the anti-amyloid monoclonal antibody aducanumab (Aduhelm) in patients with early Alzheimer’s disease.
-
C.
ENSEMBLE trial
The ENSEMBLE trial was a large, global Phase 3 clinical study designed to evaluate the safety and efficacy of Janssen’s single-dose COVID-19 vaccine in preventing SARS-CoV-2 infection and severe disease.
-
D.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
adjuvant breast cancer trial
ⓘ
phase III clinical trial ⓘ randomized controlled trial ⓘ |
| acronym | APHINITY ⓘ |
| ageGroup | adult patients ⓘ |
| allocation | randomized ⓘ |
| biomarkerStatus | HER2-positive ⓘ |
| chemotherapyBackbone |
anthracycline-based regimens
ⓘ
non-anthracycline-based regimens ⓘ |
| coDeveloperDrug |
Herceptin
ⓘ
Perjeta ⓘ |
| controlRegimen | trastuzumab plus chemotherapy ⓘ |
| controlType | placebo-controlled ⓘ |
| diseaseStage | early breast cancer ⓘ |
| drugTarget | HER2 receptor ⓘ |
| evaluatedCombination | pertuzumab plus trastuzumab plus chemotherapy ⓘ |
| evaluatedDrug |
chemotherapy
ⓘ
pertuzumab ⓘ Herceptin ⓘ
surface form:
trastuzumab
|
| fullName |
APHINITY trial
self-linksurface differs
ⓘ
surface form:
Adjuvant Pertuzumab and Herceptin IN Initial TherapY trial
|
| geographicScope |
multicenter
ⓘ
multinational ⓘ |
| impact |
influenced international breast cancer treatment guidelines
ⓘ
supported regulatory approval of pertuzumab in adjuvant HER2-positive early breast cancer ⓘ |
| indication | HER2-positive early breast cancer ⓘ |
| interventionDuration | 1 year of anti-HER2 therapy ⓘ |
| keyFinding |
addition of pertuzumab improved invasive disease-free survival in HER2-positive early breast cancer
ⓘ
benefit was greater in node-positive patients ⓘ cardiac safety profile was acceptable ⓘ |
| masking | double-blind ⓘ |
| mechanismOfActionContext | dual HER2 blockade with pertuzumab and trastuzumab ⓘ |
| population |
node-positive and high-risk node-negative patients
ⓘ
patients with operable HER2-positive breast cancer ⓘ |
| presentedAt |
American Society of Clinical Oncology
ⓘ
surface form:
American Society of Clinical Oncology Annual Meeting
|
| primaryEndpoint | invasive disease-free survival ⓘ |
| publishedIn | New England Journal of Medicine ⓘ |
| registrationType | pivotal trial ⓘ |
| reportedInitialResultsYear | 2017 ⓘ |
| safetyAssessment | cardiac function monitoring ⓘ |
| secondaryEndpoint |
cardiac safety
ⓘ
overall survival ⓘ |
| sponsor |
Genentech
ⓘ
Roche ⓘ |
| startYear | mid-2000s ⓘ |
| therapyLine | curative-intent adjuvant therapy ⓘ |
| treatmentSetting | adjuvant ⓘ |
| trialPhase | Phase III ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: APHINITY trial Description of subject: The APHINITY trial is a large phase III clinical study that evaluated the addition of pertuzumab (Perjeta) to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Adjuvant Pertuzumab and Herceptin IN Initial TherapY trial